<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Oncology Product Guide &#187; HER2 protein</title>
	<atom:link href="http://www.oncologyproductguide.com/blog/tag/her2-protein/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.oncologyproductguide.com/blog</link>
	<description>A comprehensive guide to oncology products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 12:00:01 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>FDA clearance to Ikonisys’ oncoFISH HER2 test</title>
		<link>http://www.oncologyproductguide.com/blog/2008/10/30/fda-clearance-to-ikonisys%e2%80%99-oncofish-her2-test/</link>
		<comments>http://www.oncologyproductguide.com/blog/2008/10/30/fda-clearance-to-ikonisys%e2%80%99-oncofish-her2-test/#comments</comments>
		<pubDate>Thu, 30 Oct 2008 06:48:39 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[Treatments]]></category>
		<category><![CDATA[Tumors]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[HER2 protein]]></category>
		<category><![CDATA[Herceptin (trastuzumab)]]></category>
		<category><![CDATA[Ikonisys]]></category>
		<category><![CDATA[oncoFISH HER2 test]]></category>

		<guid isPermaLink="false">http://www.oncologyproductguide.com/blog/2008/10/30/fda-clearance-to-ikonisys%e2%80%99-oncofish-her2-test/</guid>
		<description><![CDATA[The U.S. Food and Drug Administration has given clearance to Ikonisys’ oncoFISH HER2 test, a fully computerized microscopy application to determine HER2 status in human specimens of breast cancer developed with Abbott&#8217;s PathVysion® HER2 DNA Probe Kit. The company&#8217;s proprietary CellOptics® platform which features the Ikoniscope® drives the test by providing an earlier and precise [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.oncologyproductguide.com/blog/wp-content/uploads/2008/10/ikonysis.png" align="left" height="63" hspace="5" vspace="5" width="200" />The U.S. Food and Drug Administration has given clearance to <a href="http://www.ikonisys.com/">Ikonisys</a>’ oncoFISH HER2 test, a fully computerized microscopy application to determine HER2 status in human specimens of breast cancer developed with Abbott&#8217;s PathVysion® HER2 DNA Probe Kit. The company&#8217;s proprietary CellOptics® platform which features the Ikoniscope® drives the test by providing an earlier and precise indication for amplification of gene. This diagnosis reveals whether a patient is a candidate for Herceptin (trastuzumab) treatment. Higher quantity of HER2 protein can lead to rapid growth of tumor, resistance to some types of treatment, prolonged illness and reduced survival period.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.oncologyproductguide.com/blog/2008/10/30/fda-clearance-to-ikonisys%e2%80%99-oncofish-her2-test/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
